The correction of micro-circulatory disorders in strategies of management of osteoarthritis and osteohondropathies


Cite item

Full Text

Abstract

The article presents international and Russian data revealing necessity of development of new approaches to medical management under diseases of musculo-skeletal system because of considerable medical social consequences. The role of micro-circulatory disorders as a point of application of therapeutic strategies under treatment of osteoarthritis and osteohondropathy is substantiated using results of modern scientific research studies. The article presents comprehensive analysis of public statistic data, experimental and clinical studies permitting concluding that effective correction of micro-circulatory disorders can level medical and social economic consequences of considered nosologic forms. The necessity to expand studies of micro-circulation in corresponding category of patients is for development of new schemes and algorithms of treatment is substantiated. The perspective of considering correction of micro-circulatory disorders as a significant direction of management of diseases of musculo-skeletal system is demonstrated.

About the authors

Aleksey N. Vanov

The Saratov research institute of traumatology and orthopedics of Minzdrav of Russia

Email: lex558452@rambler.ru
МБ, PhD, DSc, Associate Professor, Leading Scientist 410002 Saratov, Russia

A. S Fedonnikov

The Saratov research institute of traumatology and orthopedics of Minzdrav of Russia

410002 Saratov, Russia

I. A Norkin

The Saratov research institute of traumatology and orthopedics of Minzdrav of Russia

410002 Saratov, Russia

D. M Puchinian

The Saratov research institute of traumatology and orthopedics of Minzdrav of Russia

410002 Saratov, Russia

References

  1. Jacobson L., Lindgren B. What are the costs of illness? Stockholm: Socialstyrelsen. National Board of Health and Welfare. 1996.
  2. Tsou I.Y., Chng H.H. The Bone and Joint Decade 2000-2010: for prevention and treatment of musculoskeletal disease. Ann Acad Med Singapore. 2002; 31(1): 69-70.
  3. Woolf A.D. The Bone and Joint Decade. Strategies to Reduce the Burden of Disease: the Bone and Joint Monitor Project. J. Rheumatol. 2003; 30 (67): 6-9.
  4. Lidgren L. The Bone and Joint Decade 2000-2010: for prevention and treatment of musculoskeletal disease. Bulletin of the World Health Organisation. 2003; 81 (9): 629.
  5. The Bone and Joint Decade. Global Alliance for Musculoskeletal Health. Key facts from The Global Burden of Disease 2012. Available at: http://bjdonline.org/?page_id=1574
  6. Woolf A.D., Pfleger B. Burden of major musculoskeletal conditions. Bulletin of the World Health Organization. 2003; 81 (9): 646-56.
  7. European bone and joint health strategies project. A Public Health Strategy to Reduce the Burden of Musculoskeletal Conditions. Available at: http://ec.europa.eu/health/ph_projects/2000/promotion/fp_promotion_2000_frep_15_en.pdf.
  8. Van Baar M.E., Dekker J., Lemmens J.A., Oostendorp R.A., Bijlsma J.W. Pain and disability in patients with osteoarthritis of hip or knee: the relationship with articular, kinesiological, and psychological characteristics. J. Rheumatol. 1998; 25(1): 125-33.
  9. Loeser R.F. Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clin. Geriatr. Med. 2010; 26(3): 371-86.
  10. Murray C.J.L., Lopez A.D., eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA, Harvard University Press, 2006.
  11. Global Burden of Disease and Risk Factors. The World Bank, Washington DC: Oxford University Press and the World Bank, 2006.
  12. Rasker J.J. Rheumatology in general practice. Br. J. Rheumatol. 1995; 34(6): 494-7.
  13. Mitchell J., Burhauser R. Disentangling the effect of arthritis on earnings: a simultaneous estimate of wage rates and hours worked. Applied Economics Letters. 1990; 22: 1291-310.
  14. Миронов С.П., Еськин Н.А., Андреева Т.М. Болезни костно-мышечной системы как социально-экономическая проблема. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2012; 2: 3-7.
  15. Черникова О.М., Сидорова Г.В., Арсентьева Н.И., Гаркуша Л.Г., Бакштановская Е.О. Потенциальные возможности совершенствования реабилитации пациентов с последствиями травм и заболеваниями костно-мышечной системы на региональном уровне. Медико-социальная экспертиза и реабилитация. 2012. 3: 6-8.
  16. Андреева Т.М., Огрызко Е.В., Попова М.М. Под ред. академика РАН и РАМН Миронова С.П. М: ФГБУ "ЦИТО им. Н.Н. Приорова" Минздрава России; 2012.
  17. Распределение численности лиц, впервые признанных инвалидами, по причинам инвалидности. Федеральная служба государственной статистики. Avaible at: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/healthcare/#
  18. Zhuo Q., Yang W., Chen J., Wang Y. Metabolic syndrome meets osteoarthritis. Nat. Rev. Rheumatol. 2012; 8(12): 729-37.
  19. Цвингер С.М., Говорин А.В., Алексенко Е.Ю. Маркеры эндотелиальной дисфункции при остеоартрите. Дальневосточный медицинский журнал. 2009; 3: 9-11.
  20. Murata M., Yudoh K., Masuko K. The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis? Osteoarthritis Cartilage. 2008; 16(3): 279-86.
  21. Ребров А.П., Харитонова И.А. Изменение эндотелиальной дисфункции у больных остеоартритом на фоне терапии терафлексом. Сибирский медицинский журнал. 2007; 7: 47-50.
  22. Sinusas K. Osteoarthritis: diagnosis and treatment. Am. Fam. Physician. 2012; 85(1): 49-56.
  23. Australian Institute of Health and Welfare 2007. A picture of osteoarthritis in Australia. Arthritis series no. 5. Cat. no. PHE 93. Canberra: AIHW. Avaible at: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442459825/
  24. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J. et al. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. 2012; 64(4): 465-74.
  25. National Institute for Health and Clinical Excellence 2008. Osteoarthritis: the care and management of osteoarthritis in adults. Avaible at: http://www.nice.org.uk/nicemedia/pdf/cg59niceguideline.pdf.
  26. Киричук В.Ф., Киреев С.И., Богомолова Н.В., Дулатов Р.М., Креницкий А.П. Оценка эффективности ТГЧ-терапии на частотах оксида азота в комплексном лечении пациентов с деформирующим артрозом (клинико-экспериментальное исследование). Биомедицинская радиоэлектроника. 2011; 1: 58-61.
  27. Бяловский Ю.Ю., Ларинский Н.Е., Иванов А.В. Применение низкочастотного бегущего магнитного поля в лечении остеоартрита коленных суставов. Физиотерапия, бальнеология и реабилитация. 2012; 3: 16-8.
  28. Grainger R., Cicuttini F.M. Medical management of osteoarthritis of the knee and hip joints. Med. J. 2004; 180 (5): 232-6.
  29. Hegedus B., Viharos L., Gervain M., Galfi M. The effect of low-level laser in knee osteoarthritis: a double-blind, randomized, placebocontrolled trial. Photomed. Laser Surg. 2009; 27(4): 577-84.
  30. Cannon C.P., Curtis S.P., FitzGerald G.A., Krum H., Kaur A., Bolognese J.A. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368(9549): 1771-81.
  31. Fiorucci S., Distrutti E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non-steroidal anti-inflammatory drugs. Curr. Med. Chem. 2011; 18(23): 3494-505.
  32. Amanatullah D.F., Strauss E.J., Di Cesare P.E. Current management options for osteonecrosis of the femoral head: part 1, diagnosis and nonoperative management. Am. J. Orthop (Belle Mead NJ). 2011; 40(9): E186-E92.
  33. Sarris I., Weiser R., Sotereanos D.G. Pathogenesis and treatment of osteonecrosis of the shoulder. Orthop. Clin. North. Am. 2004; 35: 397-404.
  34. Gruson K.I., Kwon Y.W. Atraumatic Osteonecrosis of the Humeral Head. Bulletin of the NYU Hospital for Joint Diseases. 2009; 67(1): 6-14.
  35. Kelly J.D., Sherwin S.W. Femoral head avascular necrosis, available at: http://emedicine.medscape.com/article/86568-overview#a0199.
  36. Lavernia C.J., Sierra R.J., Grieco F.R. Osteonecrosis of the femoral head. J. Am. Acad. Orthop. Surg. 1999; 7(4): 250-61.
  37. Бахтеева Н.Х. Профилактика развития остеоартрита у детей и подростков с патологией тазобедренного сустава: Автореф. дис.. докт. мед. наук. Самара; 2002.
  38. Шушарин А.Г., Половинка М.П., Прохоренко В.М., Шевела А.И., Власов В.В. Лечение асептического некроза ТБС с применением локальной инъекционной терапии под УЗ-контролем. Современные проблемы науки и образования. 2012; 4. Avaible at: http://www.science-education.ru/104-6807.
  39. Макушин В.Д., Сафонов В.А., Данилова И.М., Митина Ю.Л. К вопросу о ранней диагностике асептического некроза головки бедра у взрослых. Гений ортопедии. 2003; 1: 125-9.
  40. Zhu H.Y., Zhu B. Treatment of early stage avascular necrosis of the femoral head. Zhongguo Gu Shang. 2012; 25(7): 616-20.
  41. Glueck C.J., Freiberg R.A., Boppana S., Wang P. Thrombophilia, hypofibrinolysis, the eNOS T-786C polymorphism, and multifocal osteonecrosis. J. Bone. Joint. Surg. Am. 2008; 90(10): 2220-9.
  42. Chotanaphuti T., Heebthamai D., Chuwong M., Kanchanaroek K. The prevalence of thrombophilia in idiopathic osteonecrosis of the hip. J. Med. Assoc. Thai. 2009; 92 (6): 141-6.
  43. Kerachian M.A., Harvey E.J., Cournoyer D., Chow T.Y., Seguin C. Avascular necrosis of the femoral head: vascular hypotheses. Endothelium. 2006; 13(4): 237-44.
  44. Seguin C., Kassis J., Busque L., Bestawros A., Theodoropoulos J., Alonso M.-L., Harvey E.J. Non-traumatic necrosis of bone (osteonecrosis) is associated with endothelial cell activation but not thrombophilia. Rheumatology. 2008; 47(8): 1151-55.
  45. Drescher W., Pufe T., Smeets R., Eisenhart-Rothe R.V., Jager M., Tingart M. Avascular necrosis of the hip - diagnosis and treatment. Z. Orthop. Unfall. 2011; 149(2): 231-40.
  46. Sen R.K. Management of avascular necrosis of femoral head at precollapse stage. Indian J. Orthop. 2009; 43(1): 6-16.
  47. Glueck C.J., Freiberg R.A., Sieve L., Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin. Orthop. Relat. Res. 2005; 435: 164-70.
  48. Jager M., Zilkens C., Bittersohl B., Matheney T., Kozina G., Blondin D. et al. Efficiency of iloprost treatment for osseous malperfusion. Int. Orthop. 2011; 35(5): 761-65.
  49. Leo M., Milena F., Ruggero C., Stefania S., Giancarlo T. Biophysical stimulation in osteonecrosis of the femoral head. Indian J. Orthop. 2009; 43(1): 17-21.
  50. Camporesi E.M., Vezzani G., Bosco G., Mangar D., Bernasek T.L. Hyperbaric oxygen therapy in femoral head necrosis. J. Arthroplasty. 2010; 25(6): 118-23.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies